Logo image of ESPR

ESPERION THERAPEUTICS INC (ESPR) Stock Fundamental Analysis

NASDAQ:ESPR - Nasdaq - US29664W1053 - Common Stock - Currency: USD

1.82  -0.03 (-1.62%)

After market: 1.84 +0.02 (+1.1%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ESPR. ESPR was compared to 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ESPR have multiple concerns. ESPR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ESPR had negative earnings in the past year.
In the past year ESPR has reported a negative cash flow from operations.
In the past 5 years ESPR always reported negative net income.
ESPR had a negative operating cash flow in each of the past 5 years.
ESPR Yearly Net Income VS EBIT VS OCF VS FCFESPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M -250M

1.2 Ratios

ESPR has a Return On Assets of -27.62%. This is comparable to the rest of the industry: ESPR outperforms 57.30% of its industry peers.
The Return On Invested Capital of ESPR (8.77%) is better than 87.57% of its industry peers.
Industry RankSector Rank
ROA -27.62%
ROE N/A
ROIC 8.77%
ROA(3y)-88.82%
ROA(5y)-70.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESPR Yearly ROA, ROE, ROICESPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400

1.3 Margins

ESPR has a Operating Margin of 5.57%. This is in the better half of the industry: ESPR outperforms 79.46% of its industry peers.
ESPR has a Gross Margin of 81.58%. This is amongst the best in the industry. ESPR outperforms 87.57% of its industry peers.
In the last couple of years the Gross Margin of ESPR has declined.
Industry RankSector Rank
OM 5.57%
PM (TTM) N/A
GM 81.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.07%
GM growth 5YN/A
ESPR Yearly Profit, Operating, Gross MarginsESPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200 -300

More info and screens

1

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ESPR is destroying value.
ESPR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ESPR has been increased compared to 5 years ago.
The debt/assets ratio for ESPR is higher compared to a year ago.
ESPR Yearly Shares OutstandingESPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
ESPR Yearly Total Debt VS Total AssetsESPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

ESPR has an Altman-Z score of -5.07. This is a bad value and indicates that ESPR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ESPR (-5.07) is worse than 64.32% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.07
ROIC/WACC0.96
WACC9.1%
ESPR Yearly LT Debt VS Equity VS FCFESPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M -400M

2.3 Liquidity

ESPR has a Current Ratio of 1.85. This is a normal value and indicates that ESPR is financially healthy and should not expect problems in meeting its short term obligations.
ESPR's Current ratio of 1.85 is on the low side compared to the rest of the industry. ESPR is outperformed by 62.70% of its industry peers.
A Quick Ratio of 1.37 indicates that ESPR should not have too much problems paying its short term obligations.
ESPR's Quick ratio of 1.37 is on the low side compared to the rest of the industry. ESPR is outperformed by 70.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.37
ESPR Yearly Current Assets VS Current LiabilitesESPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 73.11% over the past year.
The Revenue has grown by 187.12% in the past year. This is a very strong growth!
Measured over the past years, ESPR shows a very negative growth in Revenue. The Revenue has been decreasing by -20.03% on average per year.
EPS 1Y (TTM)73.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.46%
Revenue 1Y (TTM)187.12%
Revenue growth 3Y-20.03%
Revenue growth 5YN/A
Sales Q2Q%52%

3.2 Future

The Earnings Per Share is expected to grow by 17.31% on average over the next years. This is quite good.
The Revenue is expected to grow by 36.62% on average over the next years. This is a very strong growth
EPS Next Y85.09%
EPS Next 2Y40.7%
EPS Next 3Y26.26%
EPS Next 5Y17.31%
Revenue Next Year187.95%
Revenue Next 2Y74.69%
Revenue Next 3Y49.46%
Revenue Next 5Y36.62%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ESPR Yearly Revenue VS EstimatesESPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ESPR Yearly EPS VS EstimatesESPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ESPR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ESPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESPR Price Earnings VS Forward Price EarningsESPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ESPR is valued a bit cheaper than the industry average as 78.92% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 28.91
ESPR Per share dataESPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

ESPR's earnings are expected to grow with 26.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.7%
EPS Next 3Y26.26%

More info and screens

0

5. Dividend

5.1 Amount

ESPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESPERION THERAPEUTICS INC

NASDAQ:ESPR (2/21/2025, 8:16:08 PM)

After market: 1.84 +0.02 (+1.1%)

1.82

-0.03 (-1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-04 2025-03-04/amc
Inst Owners66.23%
Inst Owner Change-93.12%
Ins Owners0.42%
Ins Owner Change-0.29%
Market Cap358.61M
Analysts78.67
Price Target6.89 (278.57%)
Short Float %15.93%
Short Ratio5.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.71%
Min EPS beat(2)-75.67%
Max EPS beat(2)16.24%
EPS beat(4)2
Avg EPS beat(4)138%
Min EPS beat(4)-75.67%
Max EPS beat(4)613.01%
EPS beat(8)5
Avg EPS beat(8)73.37%
EPS beat(12)8
Avg EPS beat(12)52.17%
EPS beat(16)10
Avg EPS beat(16)37.99%
Revenue beat(2)1
Avg Revenue beat(2)25.52%
Min Revenue beat(2)-1.37%
Max Revenue beat(2)52.41%
Revenue beat(4)3
Avg Revenue beat(4)30.64%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)61.33%
Revenue beat(8)6
Avg Revenue beat(8)16.81%
Revenue beat(12)8
Avg Revenue beat(12)12.55%
Revenue beat(16)9
Avg Revenue beat(16)4.67%
PT rev (1m)-5.26%
PT rev (3m)-10.02%
EPS NQ rev (1m)-10.19%
EPS NQ rev (3m)-10.19%
EPS NY rev (1m)-3.59%
EPS NY rev (3m)-14.47%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)0.05%
Revenue NY rev (1m)-0.45%
Revenue NY rev (3m)-4.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.21
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 28.91
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS1.5
BVpS-1.88
TBVpS-1.88
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.62%
ROE N/A
ROCE 11.1%
ROIC 8.77%
ROICexc 368.88%
ROICexgc 374.84%
OM 5.57%
PM (TTM) N/A
GM 81.58%
FCFM N/A
ROA(3y)-88.82%
ROA(5y)-70.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.07%
GM growth 5YN/A
F-Score6
Asset Turnover0.94
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 15.94
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.37
Altman-Z -5.07
F-Score6
WACC9.1%
ROIC/WACC0.96
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.46%
EPS Next Y85.09%
EPS Next 2Y40.7%
EPS Next 3Y26.26%
EPS Next 5Y17.31%
Revenue 1Y (TTM)187.12%
Revenue growth 3Y-20.03%
Revenue growth 5YN/A
Sales Q2Q%52%
Revenue Next Year187.95%
Revenue Next 2Y74.69%
Revenue Next 3Y49.46%
Revenue Next 5Y36.62%
EBIT growth 1Y110.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.31%
EBIT Next 3Y31.09%
EBIT Next 5Y17.55%
FCF growth 1Y86.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.45%
OCF growth 3YN/A
OCF growth 5YN/A